Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.[ Read More ]
The intrinsic value of one BFRIW stock under the base case scenario is HIDDEN Compared to the current market price of 0.0699 USD, Biofrontera Inc. is HIDDEN
Price Chart BFRIW
| Current Assets | 23.1 M |
| Cash & Short-Term Investments | 1.42 M |
| Receivables | 5.16 M |
| Other Current Assets | 16.5 M |
| Non-Current Assets | 4.86 M |
| Long-Term Investments | 0 |
| PP&E | 1.75 M |
| Other Non-Current Assets | 3.11 M |
| Current Liabilities | 18.1 M |
| Accounts Payable | 9.01 M |
| Short-Term Debt | 5.29 M |
| Other Current Liabilities | 3.8 M |
| Non-Current Liabilities | 5.05 M |
| Long-Term Debt | 804 K |
| Other Non-Current Liabilities | 4.25 M |
| Revenue | 34.1 M |
| Cost Of Revenue | 17.4 M |
| Gross Profit | 16.6 M |
| Operating Expenses | 40 M |
| Operating Income | -22.7 M |
| Other Expenses | -2.55 M |
| Net Income | -20.1 M |
| Net Income | -20.1 M |
| Depreciation & Amortization | 1.06 M |
| Capital Expenditures | -5 K |
| Stock-Based Compensation | 1.04 M |
| Change in Working Capital | -4.39 M |
| Others | -14.5 M |
| Free Cash Flow | -24.9 M |
| Date | Value | Insider | Amount | Avg Price |
|---|
Biofrontera Inc. BFRIW